01—Abstract
Summary
Summary of the 8-K filed November 10, 2025. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (Nasdaq: ROIV) reported financial results for the quarter ended September 30, 2025, and provided a business update.
The company's headline clinical news is that brepocitinib 30 mg met the primary endpoint and all nine key secondary endpoints versus placebo in the Phase 3 VALOR study in dermatomyositis, with an NDA filing planned for the first half of calendar year 2026. CEO Matt Gline described the quarter as "a moment of transformation" for the company. Immunovant's 24-week uncontrolled Graves' disease study also showed what the filing calls a first-ever potentially disease-modifying outcome, based on six-month off-treatment data.
On financials, research and development expenses rose to $164.6 milliona from $143.1 million, driven mainly by program-specific costs and personnel-related expenses tied to the anti-FcRn franchise and brepocitinib. General and administrative expenses fell to $143.1 million from $202.9 million, mainly because the prior-year quarter included one-time cash retention awards. Loss from continuing operations, net of tax, was $166.0 million, or $0.17 per share, compared with $236.8 million, or $0.25 per share, a year earlier.
The company reported consolidated cash, cash equivalents, restricted cash and marketable securities of $4.4 billionb as of September 30, 2025, which it says supports cash runway into profitability. The filing also outlines a dense set of milestones. These include a brepocitinib proof-of-concept readout in cutaneous sarcoidosis in the second half of calendar year 2026, a Phase 3 non-infectious uveitis readout in the first half of 2027, and two batoclimab thyroid eye disease Phase 3 studies now expected to read out concurrently in the first half of 2026.
Genevant's LNP litigation continues, with a jury trial in the U.S. Moderna case scheduled for March 2026. Roivant will hold an Investor Day on December 11, 2025.
02—Key points
Key Highlights
- Brepocitinib 30 mg met the primary endpoint and all nine key secondary endpoints versus placebo in the Phase 3 VALOR study in dermatomyositis; NDA filing planned for the first half of calendar year 2026.
- Immunovant's Graves' disease study in uncontrolled patients showed a first-ever potentially disease-modifying outcome with six-month off-treatment data; the two batoclimab thyroid eye disease Phase 3 studies are now expected to report concurrently in the first half of 2026.
- R&D expenses increased to $164.6 million from $143.1 million, driven by program-specific costs (up $13.2 million) and personnel-related expenses (up $7.1 million).
- G&A expenses decreased to $143.1 million from $202.9 million, mainly due to lower personnel-related expense, including prior-year one-time cash retention awards.
- Loss from continuing operations, net of tax, narrowed to $166.0 million ($0.17 per share) from $236.8 million ($0.25 per share); non-GAAP loss from continuing operations was $187.8 million versus $218.7 million.
- Consolidated cash, cash equivalents, restricted cash and marketable securities totaled $4.4 billion as of September 30, 2025, which the company says supports cash runway into profitability.
- Genevant LNP litigation is progressing, with a favorable Markman ruling in the Pfizer/BioNTech case in September 2025 and a U.S. Moderna jury trial scheduled for March 2026; Investor Day is set for December 11, 2025.
03—Questions
Frequently Asked Questions
What was the key clinical news in this quarter's update?
Brepocitinib 30 mg demonstrated clinically meaningful and statistically significant improvement versus placebo on the primary endpoint and all nine key secondary endpoints in the Phase 3 VALOR study in dermatomyositis. The company plans to file an NDA in the first half of calendar year 2026. The safety profile was consistent with prior brepocitinib trials.
How did Roivant's operating expenses change year over year?
R&D expenses rose by $21.5 million to $164.6 million, driven by program-specific costs and personnel expenses supporting the anti-FcRn franchise and brepocitinib. G&A expenses fell by $59.8 million to $143.1 million, largely because the prior-year quarter included one-time cash retention awards.
What is the company's liquidity position?
Roivant reported consolidated cash, cash equivalents, restricted cash and marketable securities of approximately $4.4 billion as of September 30, 2025. The company states this supports cash runway into profitability.
What upcoming catalysts should investors watch?
Key catalysts include the brepocitinib proof-of-concept readout in cutaneous sarcoidosis in the second half of calendar year 2026, the Phase 3 non-infectious uveitis readout in the first half of 2027, and the concurrent batoclimab thyroid eye disease Phase 3 readouts in the first half of 2026. The Genevant U.S. Moderna jury trial is scheduled for March 2026, and Roivant will host an Investor Day on December 11, 2025.
04—Continue